Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies.
Joraku A, Hatano K, Kawai K, Kandori S, Kojima T, Fukumitsu N, Isobe T, Mori Y, Sakata M, Hara T, Nasu K, Minami M, Iizumi Y, Nishiyama H.
Joraku A, et al. Among authors: hatano k.
Ann Nucl Med. 2019 Feb;33(2):119-127. doi: 10.1007/s12149-018-1312-6. Epub 2018 Nov 7.
Ann Nucl Med. 2019.
PMID: 30406361
Clinical Trial.